Emerging transmitted drug resistance in treatment-naïve human immunodeficiency virus-1 CRF06_cpx-infected patients in Estonia
| Autor: | Kristi Huik, Külliki Ainsalu, Tõnu Krispin, Radko Avi, Valentina Ustina, Jelena Schmidt, Irja Lutsar, Tõnis Karki, Piret Paap, Merit Pauskar, Natalia Nikitina |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Microbiology (medical)
Estonia Male Genotype medicine.medical_treatment Population Molecular Sequence Data Mutation Missense HIV Infections Drug resistance Virus law.invention law Drug Resistance Viral medicine Humans education Recombination Genetic education.field_of_study Chemotherapy General Immunology and Microbiology Reverse-transcriptase inhibitor biology General Medicine Sequence Analysis DNA Resistance mutation biology.organism_classification Virology Infectious Diseases Amino Acid Substitution Lentivirus Recombinant DNA HIV-1 RNA Viral Female medicine.drug |
| Zdroj: | Scandinavian journal of infectious diseases. 43(2) |
| ISSN: | 1651-1980 |
| Popis: | Human immunodeficiency virus (HIV)-1 transmitted drug resistance in the drug-naïve population is of growing relevance in Estonia, where the number of antiretroviral (ARV) treatment-experienced subjects has been exponentially increasing during the last 10 y. The aim of this study was to estimate the rate of transmitted drug resistance among newly diagnosed subjects in Estonia in 2008. Genotypic resistance testing for viral genomic RNA was conducted for 201 subjects tested HIV-positive between 1 April and 30 November 2008. Of 145 genotyped viral strains in newly diagnosed patients, 123 were CRF06_cpx, 2 were subtype A1 and 3 were subtype B; in 17 cases viral sequences revealed recombinant structures similar to CRF06_cpx, subtype A1 and CRF02_AG. Resistance mutations were found in 8 (5.5%) virus strains, and 3 strains were resistant to at least 2 ARV classes. A total of 2.8% of sequences harboured mutations indicating nucleoside/nucleotide reverse transcriptase inhibitor resistance (M41L, M184V, M184I, T215C and T215D), 2.1% non-nucleoside reverse transcriptase inhibitor resistance (K103N, P225H) and 2.8% protease inhibitor resistance (M46I, L90M). These data suggest the need to extend genotypic HIV-1 drug resistance testing to newly diagnosed HIV-positive subjects to prevent potential ARV treatment failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|